Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Funder: Canadian Institutes of Health Research

Funding period
CAD 181 K
USD 139 K
Funding amount
Abstract
Radical cystectomy remains the standard of care for muscle-invasive bladder cancer (MIBC). This surgery entails complete removal of the bladder and surrounding organs, leading to a serious impact on the quality of life (QoL) of patients and associated with a 5-year overall survival of only 50 %. Radiation therapy (RT), which preserves the bladder, would be a more appropriate treatment modality if we could improve efficacy, as lack of local control remains problematic. As part from its direct tumor cell killing potential, there is increasing evidence that RT also leads to significant alterations in the tumor microenvironment, which inflammation being one of the most important factors modulating radiation responsiveness of tumors. During the acute phase of inflammation, neutrophils are one of the first-line responders of inflammatory cells to migrate towards the site of inflammation. Recently, it has been shown neutrophils can exhibit dual behaviors and are increasingly being seen as important players in cancer progression. Neutrophils can expel DNA studded with various proteins to form web-like structures known as neutrophil extracellular traps (NET), which has been shown to be associated with tumor progression and metastasis. Our preliminary findings strongly indicate NET are implicated in radioresistance. Determining the NET-related molecular and cellular mechanisms underlying response to radiation will have direct clinical relevance to better select patients who will benefit most from bladder preservation therapy. The novel approach of the proposal herein can bring transformative changes in developing novel strategies in bladder cancer (BC) therapy as it has the potential to transfer from the bench to the patient, an unquestionably, positive impact on survival and quality of life of MIBC patients.
Similar projects All >
Sorted by: Start Date
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science